zrickety said:
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html
Key Updates for Week 38, ending September 19, 2020
Nationally, indicators that track COVID-19 activity continued to decline or remain stable (change of ≤0.1%); however, three regions reported an increase in the percentage of specimens testing positive for SARS-CoV-2, the virus causing COVID-19, and one of those regions also reported an increase in the percentage of visits for influenza-like illness (ILI) and COVID-like illness (CLI) to emergency departments (EDs). Mortality attributed to COVID-19 declined but remains above the epidemic threshold.
Virus
Public Health, Commercial and Clinical Laboratories
Nationally, the percentage of respiratory specimens testing positive for SARS-CoV-2 decreased from 5.1% during week 37 to 4.8% during week 38. National percentages of specimens testing positive for SARS-CoV-2 by type of laboratory are listed.
- Public health laboratories – increased from 4.6% during week 37 to 5.1% during week 38
- Clinical laboratories – decreased from 6.0% during week 37 to 5.4% during week 38
- Commercial laboratories – decreased from 5.0% during week 37 to 4.6% during week 38
Outpatient and Emergency Department Visits
Outpatient Influenza-Like Illness Network (ILINet) and National Syndromic Surveillance Program (NSSP)
Two surveillance networks are being used to track outpatient or emergency department (ED) visits for illness with symptoms compatible with COVID-19.
- Nationally, ILI activity remains below baseline for the 23rd consecutive week and is at levels that are typical for this time of year.
- Nationally, the percentage of visits for ILI reported by ILINet participants and the percentage of visits for COVID-like illness (CLI) reported to NSSP remained stable (change of ≤0.1%) in week 38 compared with week 37.
- Recent changes in health care seeking behavior, including increasing use of telemedicine, recommendations to limit ED visits to severe illnesses, and increased social distancing, are likely affecting both networks, making it difficult to draw conclusions at this time. Tracking these systems moving forward will give additional insight into illness related to COVID-19.
Severe Disease
Hospitalizations
Cumulative COVID-19-associated hospitalization rates since March 1, 2020, are updated weekly. The overall cumulative COVID-19 hospitalization rate is 174.8 per 100,000, with the highest rates in people aged 65 years and older (472.3 per 100,000) and 50–64 years (261.5 per 100,000).
Mortality
Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 38 is 6.6%. This is currently lower than the percentage during week 37 (9.8%); however, the percentage remains above the epidemic threshold and will likely increase as more death certificates are processed.
All data are preliminary and may change as more reports are received.
A description of the surveillance systems summarized in COVIDView, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.
Key Points
- Nationally, since mid-July, there has been an overall decreasing trend in the percentage of specimens testing positive for SARS-CoV-2 and a decreasing or stable (change of ≤0.1%) trend in the percentage of visits for ILI and CLI; however, there has been some regional variation.
- Using combined data from the three laboratory types, the national percentage of respiratory specimens testing positive for SARS-CoV-2 with a molecular assay decreased from 5.1% during week 37 to 4.8% during week 38.
- Regionally, the percentage of respiratory specimens testing positive for SARS-CoV-2 increased in Regions 7 (Central), 8 (Mountain) and 10 (Pacific Northwest) and decreased or remained stable in the remaining seven regions.
- The highest percentage of specimens testing positive for SARS-CoV-2 were seen in Regions 6 (South Central, 8.3%) and 7 (Central, 9.0%).
- The percentage of outpatient or ED visits to ILINet providers for ILI is below baseline nationally and in all 10 regions of the country.
- Compared with week 37, the percentage of visits for ILI during week 38 remained stable nationally and decreased or was stable (change of ≤0.1%) in all 10 regions.
- Nationally, the percentage of visits to EDs for CLI and ILI remained stable (change of ≤0.1%) in week 38 compared with week 37. This is the tenth consecutive week of a declining or stable percentage of visits for CLI and ILI.
- Region 8 (Mountain) reported an increase in the percentage of visits for both CLI and ILI in week 38 compared to week 37. The remaining nine regions reported a stable (change of ≤0.1%) or decreasing percentage.
- The overall cumulative COVID-19-associated hospitalization rate was 174.8 per 100,000; rates were highest in people 65 years of age and older (472.3 per 100,000) followed by people 50–64 years (261.5 per 100,000).
- From the week ending August 1 (MMWR week 31) to the week ending September 19 (MMWR week 38), weekly hospitalization rates declined for all adult age groups. However, over this same time period, weekly rates remained steady for the pediatric age groups. Data for the most recent weeks may change as additional admissions occurring during those weeks are reported.
- Age-adjusted hospitalization rates for Hispanic or Latino persons and non-Hispanic Black persons were both approximately 4.6 times that of non-Hispanic White persons. The age-adjusted hospitalization rate for non-Hispanic American Indian or Alaska Native persons was approximately 4.5 times that of non-Hispanic White persons.
- Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 38 was 6.6%, which was lower than the percentage during week 37 (9.8%), but above the epidemic threshold. These percentages will likely increase as more death certificates are processed.
- All surveillance systems aim to provide the most complete data available. Estimates from previous weeks are subject to change as data are updated with the most complete data available.
U.S. Virologic Surveillance
The number of specimens tested for SARS-CoV-2 using a molecular assay and reported to CDC by public health laboratories and a subset of clinical and commercial laboratories in the United States are summarized below. All laboratories are performing primary diagnostic functions; therefore, the percentage of specimens testing positive across laboratory types can be used to monitor overall trends in COVID-19 activity. As the outbreak progresses, it is possible that different types of laboratories will take on different roles, and the data interpretation may need to change.
Summary of Laboratory Testing Results Reported to CDC
Summary of Laboratory Testing Results Reported to CDC* | Week 38 (Sept. 13–Sept. 19, 2020) | Cumulative since March 1, 2020 |
---|---|---|
No. of specimens tested | 2,029,130 | 51,075,554 |
Public Health Laboratories | 294,153 | 6,159,942 |
Clinical Laboratories | 175,308 | 5,848,708 |
Commercial Laboratories | 1,559,669 | 39,066,904 |
No. of positive specimens (%) | 96,477 (4.8%) | 4,163,115 (8.2%) |
Public Health Laboratories | 15,074 (5.1%) | 464,343 (7.5%) |
Clinical Laboratories | 9,509 (5.4%) | 357,369 (6.1%) |
Commercial Laboratories | 71,894 (4.6%) | 3,341,403 (8.6%) |
* Commercial and clinical laboratory data represent select laboratories and do not capture all tests performed in the United States.
Public Health Laboratories
resize iconView Larger
View Data Table
Clinical Laboratories
resize iconView Larger
View Data Table
Commercial Laboratories
resize iconView Larger
* Commercial laboratories began testing for SARS-CoV-2 in early March, but the number and geographic distribution of reporting commercial laboratories became stable enough to calculate a weekly percentage of specimens testing positive as of March 29, 2020.
View Data Table
Additional virologic surveillance information: Surveillance Methods
Outpatient/Emergency Department Illness
Two syndromic surveillance systems are being used to monitor trends in outpatient and emergency department (ED) visits that may be associated with COVID-19 illness. Each system monitors a slightly different syndrome, and together, these systems provide a more comprehensive picture of mild-to-moderate COVID-19 illness than either would individually. Both systems are currently being affected by changes in health care seeking behavior, including increased use of telemedicine, compliance with recommendations to limit ED visits to severe illnesses, and increased social distancing. These changes affect the numbers of people seeking care in the outpatient and ED settings and their reasons for doing so.
ILINet
The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) provides data on visits for influenza-like illness (ILI) (fever [≥100○F] and cough and/or sore throat) to approximately 2,600 primary care providers, emergency departments, and urgent care centers in all 50 states, Puerto Rico, the District of Columbia, and the U.S. Virgin Islands. Mild COVID-19 illness presents with symptoms similar to ILI, so ILINet is being used to track trends of mild-to-moderate COVID-19 illness and allows for comparison with prior influenza seasons.
Nationwide during week 38, 1.0% of patient visits reported through ILINet were due to ILI. This percentage is well below the national baseline of 2.4% and is typical for this time of year compared to previous influenza seasons. Compared with week 37, the percentage of visits for ILI during week 38 slightly increased overall and among those aged 0 to 4 years and 25 to 49 years.
resize iconView Larger
* Age-group specific percentages should not be compared with the national baseline.
On a regional levelexternal icon, the percentage of outpatient visits for ILI ranged from 0.6% to 1.4% during week 38 and was below the region-specific baseline in all regions. Compared with week 37, the percentage during week 38 decreased slightly in regions 6 (South Central) and 7 (Central) and remained stable (change of ≤0.1%) in the remaining eight regions.
Note: In response to the COVID-19 pandemic, new data sources are being incorporated into ILINet through the summer weeks, when lower levels of influenza and other respiratory virus circulation are typical. Starting in week 21, enrollment of new sites began, leading to increases in the number of patient visits. While all regions remain below baseline levels for ILI, these system changes should be considered when drawing conclusions from these data. Any changes in ILI due to changes in respiratory virus circulation will be highlighted here.
Overall Percentage of Visits for ILI | Age Group ILI Data
ILI Activity Levels
Data collected in ILINet are used to produce a measure of ILI activity for all 50 states, Puerto Rico, the U.S. Virgin Islands, the District of Columbia, and New York City. The mean reported percentage of visits due to ILI for the current week is compared with the mean reported during non-influenza weeks, and the activity levels correspond to the number of standard deviations below, at, or above the mean.
The number of jurisdictions at each activity level during week 38 and changes compared with the previous week are summarized in the table below and shown in the following maps.
ILI Activity Levels
Activity Level | Number of Jurisdictions |